Peripheral T cell lymphoma: new model + new insight.

James C Mulloy

Open access · bronzeAbstract readComment

In one paragraph

Article in The Journal of experimental medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

1.3field-weighted citation impact, top 20% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies.Cells · 2026
Review
Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.Cells · 2021
Review
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Nature · 2017
Article
Overview of the Use of Murine Models in Leukemia and Lymphoma Research.Frontiers in oncology · 2017
Review
Characterization of a new mouse model for peripheral T cell lymphoma in humans.PloS one · 2011
Article

4 · The record

Corrections and comments

Comment on
The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.2010

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. james.mulloy@cchmc.org

Cincinnati Children's Hospital Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nonreceptor tyrosine kinase SYK has recently received a good deal of attention as a critical oncogene in various hematologic malignancies. A newly developed model of peripheral T cell lymphoma (PTCL) using the ITK-SYK fusion gene should serve as a powerful tool to dissect the signaling cascades important for SYK-associated malignancy in the context of t(5;9) PTCL.

Indexed as

AnimalsChromosomes, Human, Pair 5Chromosomes, Human, Pair 9Disease Models, AnimalHematologic NeoplasmsHumansIntracellular Signaling Peptides and ProteinsLymphoma, T-Cell, PeripheralMiceOncogenesProtein-Tyrosine KinasesRecombinant Fusion ProteinsSyk KinaseT-LymphocytesTranslocation, Geneticemt protein-tyrosine kinaseIntracellular Signaling Peptides and ProteinsProtein-Tyrosine KinasesRecombinant Fusion ProteinsSyk KinaseSYK protein, humanSyk protein, mouse

Identifiers

PMID20439538

DOI10.1084/jem.20100608

PMCPMC2867292

OpenAlexW1976728020

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-SA

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.